Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01508832 · ClinicalTrials.gov registry record · Phase 4
Determination of the Duration of Action of a Lidocaine and a Bupivacaine Digital Nerve Block in Human Volunteers
A Phase 4 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
NCT01508832 is a Phase 4 study that has completed, run by University of California, San Francisco. The registered enrollment target is 12 participants.
The verdict
NCT01508832, a Phase 4 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
Study Summary
The duration of the autonomic (sympathetic) block will last longer than the sensory block. The duration of the increased perfusion index will last longer than either the sympathetic or sensory block.
Interventions
- DRUG Lidocaine Digital Nerve Block
- DRUG Bupivacaine Digital Block
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01508832
The ClinicalTrials.gov registry entry for NCT01508832 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lidocaine Digital Nerve Block is the first listed.
NCT01508832 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01508832 about?
NCT01508832 is a clinical study titled "Determination of the Duration of Action of a Lidocaine and a Bupivacaine Digital Nerve Block in Human Volunteers". The duration of the autonomic (sympathetic) block will last longer than the sensory block. The duration of the increased perfusion index will last longer than either the sympathetic or sensory block.
What is the current status of trial NCT01508832?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2012-01.
What interventions are being tested in trial NCT01508832?
The interventions under investigation include: Lidocaine Digital Nerve Block (DRUG), Bupivacaine Digital Block (DRUG).
Who is sponsoring clinical trial NCT01508832?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.